Tetramethoxyluteolin

Tetramethoxyluteolin is a flavonoid, one of a large class of plant-derived polyphenols, and specifically a fully methylated analogue of luteolin. Luteolin carries hydroxyl groups at the 3', 4', 5, and 7 positions; in tetramethoxyluteolin each of these is converted to a methoxy group, so the compound is also named 3',4',5,7-tetramethoxyflavone. Adding methyl groups is a common strategy for flavonoids because methylation tends to increase metabolic stability and lipophilicity, helping the molecule resist rapid breakdown and enter cells more readily. In the research literature the compound is frequently referred to by the shorthand methoxyluteolin ^[2][3].

Much of the work on tetramethoxyluteolin has grown out of research into mast cells, the immune cells that release histamine and a range of inflammatory mediators and that are central to allergic reactions and to many inflammatory conditions. In cultured human mast cells, the compound has repeatedly blunted the release of pro-inflammatory molecules triggered by combinations of the neuropeptide substance P and the cytokine IL-33: it reduced secretion and gene expression of tumor necrosis factor ^[3], of interleukin-1 beta together with the enzyme machinery that generates it ^[2], and of the chemokines CCL5 and CCL2 stimulated through MAPK and NF-kappaB signaling ^[4]. These studies, largely from a single academic laboratory, positioned tetramethoxyluteolin as a candidate anti-inflammatory agent.

The compound has also been examined outside mast cells. In human keratinocytes, the skin cells whose overgrowth and inflammation characterize psoriasis, tetramethoxyluteolin inhibited tumor-necrosis-factor-driven secretion of interleukin-6, the chemokine CXCL8, and vascular endothelial growth factor by blocking the mTOR signaling pathway, and it did so as potently as established mTOR inhibitors in that setting ^[1]. On the basis of such findings it has been discussed as a possible starting point for treatments of allergic, inflammatory, and skin diseases, and it has drawn interest in conditions linked to mast cell activation.

Tetramethoxyluteolin is an experimental compound rather than an approved drug. It has appeared in dietary supplement and topical formulations marketed for purported anti-inflammatory and mast-cell-stabilizing properties, but the evidence base consists mainly of cell-culture experiments and mechanistic studies, without the large human clinical trials needed to establish medical benefit or long-term safety ^[1][2]. As a flavonoid derivative it is not a controlled substance, and it is generally handled as a research chemical or supplement ingredient.

Tetramethoxyluteolin (methoxyluteolin, a methylated flavone derivative of luteolin) has only limited human safety data, drawn mainly from a small tolerability study of a topical skin lotion in which it was generally well tolerated without affecting mast-cell viability at inhibitory concentrations. Its systemic safety in humans is essentially uncharacterized, and no formal oral toxicology, drug-interaction, or long-term data are published. Its parent flavonoid luteolin has been associated with nausea, vomiting, and gastric hypersecretion, so gastrointestinal upset is a plausible caution by analogy though not documented for the methylated form. As an investigational anti-inflammatory flavonoid it lacks the controlled clinical safety record of an approved drug and should be viewed accordingly.